Tas-102
Dynamic Tumor Resistance
M.D. Anderson Cancer CenterunclassifiedPhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 81/ 100
Competitive context
11 Active assets in the Dynamic Tumor Resistance cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cetuximab National Cancer Institute (NCI) | Phase 1 | CCC |
FLUOROURACILUM M.D. Anderson Cancer Center | Phase 1 | CC |
Calcium folinate pentahydrate M.D. Anderson Cancer Center | Phase 1 | CC |
Trastuzumab Deruxtecan M.D. Anderson Cancer Center | Phase 1 | CC |
Trifluridine M.D. Anderson Cancer Center | Early Phase 1 | C |
View all 11 →
Same molecule, other indications
Tas-102 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →